Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | Treatment options for DLBCL patients who relapse after CAR-T cell therapy

Enrico Derenzini • 25 Oct 2022
SOHO Italy 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Prexasertib Venetoclax

In this video, Enrico Derenzini, MD, PhD, European Institute of Oncology, Milan, Italy, highlights the important role of bispecific antibodies as a treatment option for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CD19 CAR-T therapy, and further discusses pre-clinical trials in this space. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Enrico Derenzini

5:08
Updates on novel agents in development for aggressive B-cell lymphoma
Enrico Derenzini • 25 Oct 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals